METAPRO: Metagenomics and genomic approaches for the prevention of the spread of plazomicin resistance in humans, animals and the environment
Plazomicin is a novel semisynthetic aminoglycoside approved in June 2018 by the FDA to be used as a last resort antibiotic in complicated urinary tract infections (UTI) caused by multidrug resistant Gram-negative bacteria in humans. Approval by the EMEA is foreseen in 2019. However, the expression of acquired 16S rRNA methyltransferases by bacteria results in complete resistance to plazomicin. Added to the high level of resistance to this novel compound, bacteria harbouring these determinants show resistance to all clinically relevant aminoglycosides. We identified in 2005 worldwide the first bacterium from animal origin bearing one such 16S rRNA methyltransferase. Since, us and other researchers have identified 13 of such methyltransferases, and they have been found in human, animal, food and environmental sources. Recent studies show that, despite not being as prevalent as other resistance mechanisms, these methyltransferases are already globally present, jeopardizing the use of this critically needed antibiotic
Bosco Rodríguez Matamoros
About me: Since I was a child, I have always had great interest in health sciences and animals, which is why I decided to study Veterinary Medicine in Madrid. During my degree I developed a special curiosity for microbiology and in the ability of bacteria to evolve and adapt, particularly in the case of antimicrobial resistance. Therefore, I realised an Internship in the US to study the epidemiology of MRSA in pigs. Afterwards I returned to Madrid to continue my formation working on the molecular bases of resistance to aminoglycosides. On a more personal aspect, I like videogames, I’m a book enthusiast and, overall, I love sports.
What motivated me to do a PhD: As a veterinarian I find myself more related to the scientific part of my profession than to the clinical one. My fascination with AMR and its implications on Public Health led me decide to start a PhD and pursue a research career. With my background, I find METAPRO really attractive, since it matches my interests and research experience perfectly. In addition, this OHEJP Doctoral Program offers me the possibility to complement my competences and skills and to be part of an amazing network of scientists, which can be key for my future professional aspirations.